FSSAI challenges Nestle India, Zydus over unsubstantiated product claims

The Food Safety and Standards Authority of India (FSSAI) has escalated scrutiny of misleading marketing practices by serving notices to Nestle India and Zydus Wellness Limited, two of the country's largest nutrition product manufacturers. The regulatory action focuses on alleged unsubstantiated claims made for three products: Lactogen Pro 1, Nan Excella Pro Stage 1, and Complan, widely consumed across Indian households.

The notices require the companies to provide scientific and clinical evidence supporting the health and nutritional benefits claimed on product packaging and in advertising materials. The FSSAI's action underscores growing concerns about manufacturers making assertions without adequate substantiation, particularly for infant and child nutrition formulations where regulatory compliance is paramount.

This enforcement drive aligns with the FSSAI's broader mandate to protect consumer interests and ensure product claims are truthful and scientifically validated. Infant formula and nutritional supplements occupy a particularly sensitive category under food regulations, given their impact on child development and maternal health. The regulator has intensified monitoring of such products following previous instances of misleading claims in the sector.

The companies now face a specified timeline to respond to the notices with documentary evidence supporting their product claims. Non-compliance or inadequate substantiation could result in penalties ranging from product recalls to monetary fines and potential restrictions on marketing claims. The development signals the FSSAI's commitment to tightening oversight of the nutrition products industry, which has faced intermittent scrutiny over labeling practices and health assertions.